HR1806-119

What This Bill Does

The Triple-Negative Breast Cancer Research and Education Act creates a focused Public Health Service Act program for a more aggressive breast cancer subtype. The bill's findings emphasize that triple-negative breast cancer lacks estrogen, progesterone, and excess HER2 receptors; is often treated with surgery, radiation, or chemotherapy rather than hormone or receptor-targeted therapy; disproportionately affects African-American and Hispanic women; and lacks adequate data on incidence, prevalence, treatment cost, prevention, and cure. It directs the NIH Director to expand, intensify, and coordinate research through institutes including NICHD, NIEHS, the Office of Research on Women's Health, and the National Institute on Minority Health and Health Disparities. It directs CDC to disseminate public information on incidence, minority women's elevated risk, and treatment options, directs HRSA to educate providers, defines minority women by cross-reference to section 1707(g), and authorizes such sums as necessary for fiscal years 2026 through 2031 for research, public education, and provider education.

Who Benefits and How

Women with triple-negative breast cancer benefit from federal research and education focused on an aggressive cancer subtype. African-American and Hispanic women benefit because the bill targets elevated risk among minority women. Cancer researchers benefit from NIH coordination and authorized funding for triple-negative breast cancer studies. Health care providers benefit from HRSA-disseminated information on current treatment options and risk patterns.

Who Bears the Burden and How

The National Institutes of Health must expand, intensify, and coordinate research across multiple institutes and offices. The Centers for Disease Control and Prevention must develop and disseminate public information on triple-negative breast cancer. The Health Resources and Services Administration must prepare provider-facing information. Federal taxpayers bear the cost of such sums as Congress appropriates for fiscal years 2026 through 2031.

Key Provisions

• Directs NIH to expand and coordinate triple-negative breast cancer research.
• Requires CDC public education on incidence, prevalence, elevated minority risk, and treatment options.
• Requires HRSA provider education on current information and treatment options.
• Authorizes such sums as necessary for fiscal years 2026 through 2031.